Mounjaro Pushes Australia’s Drug Pricing Debate | Sydney News

Eli Lilly’s CEO David Ricks is pushing hard to get Mounjaro onto Australia’s PBS, calling the previous pricing standoff “not realistic” — but he’s not giving up. While the advisory committee endorsed the drug, Lilly walked away over terms they deemed unworkable, warning that low Australian prices could hurt global R&D funding. Ricks insists they’re seeking a fair deal, not just any access. Separately, he voiced cautious hope regarding a U.S. executive order on childhood vaccines, urging scientists to challenge unfounded autism-vaccine links — stressing that any changes must be backed by solid evidence, not speculation. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4ea68ea993481845